SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and strong delivery guidance, fueling community excitement over a potential short squeeze and comparisons to past EV growth rallies, despite facing immediate price resistance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is highly volatile amid conflicting reports surrounding the Strait of Hormuz, ranging from US intelligence indications of potential Iranian mining to a retracted government claim of naval escorts. This geopolitical uncertainty, coupled with political statements about the Iran conflict nearing its end, is fueling community debate over market manipulation and global oil supply stability.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending significantly ahead of its earnings call, with market participants heavily debating its aggressive AI data center investments, the associated debt, and the status of key cloud partnerships. The community is focused on whether its substantial cloud growth and AI backlog can offset concerns about capital expenditures, positioning this event as a critical read for the broader AI infrastructure sector.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power is trending with soaring investor enthusiasm, driven by its recently secured EPA, UK, and EU regulatory clearances for its ultra-pure graphene and strong anticipation of major commercial contracts and a NASDAQ uplisting. The community widely views the company as a potential leader for the "graphene age," poised to revolutionize diverse sectors from defense to AI data centers.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is seeing extreme volatility, with community discussion centered on conflicting reports about the Strait of Hormuz
Aquickly deleted government claim of a navy escort was followed by intelligence suggesting Iran is deploying mines, leading to sharp market swings and widespread accusations of manipulation.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense volatility driven by rapidly changing geopolitical headlines from the Middle East, with the community actively debating market manipulation tactics as the index demonstrates surprising resilience through sharp recoveries.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is experiencing high volume and robust discussion following strong Q4 earnings, which showed accelerated sales of its flagship rare disease drug, MIPLYFFA. The market is re-evaluating ZVRA's potential as it transitions to a profitable commercial-stage company, with many in the community anticipating further upside ahead of potential European approval.

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

Polaryx Therapeutics is seeing massive community interest and extreme price swings, with chatter focusing on a potential short squeeze and its clinical-stage pipeline for rare diseases, catalyzed by recent news regarding its Phase 2 trial and unusual pre-market volatility.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech Inc. (CITR) is generating strong trading momentum and community buzz due to its presentation at the iAccess Alpha conference, showcasing its differentiated fire-retardant wood technology, with its low share float driving speculation of a significant re-rating if commercial traction continues.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is making new all-time highs and fueling bullish community sentiment following its transformative acquisition of Covelya Group, integrating key subsea technologies to become a dominant player in underwater defense and marine infrastructure. Investors are actively discussing its strategic expansion, crucial partnerships, and potential future NASDAQ uplisting.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Needham⬆️the PT on $CYTK to $85 and reiterated at a Buy rating. 
$BMY $EWTX 
Needham said in its note: 
There was little in terms of a Myqorzo launch update in CYTK&#39;s 4Q25 update given the product only became commercially available in late-Jan. It will take 2-3 quarters to see how the launch is tracking and compares vs. Camzyos which generated sales of~$53MM in its first 4 qrtrs of launch. 
 
The upcoming 2Q26 readout of ACACIA-HCM in nHCM represents the key catalyst for CYTK, given its potential to not only meaningfully expand (potentially double) Myqorzo&#39;s market potential into nHCM but also significantly differentiate vs. Camzyos. 
 
We expect results in early-2Q26, with success likely achieved by meeting one or both of the dual primary endpoints (KCCQ or pVO2). 
 
We maintain our Buy rating and increase our $ PT to $85 (from $84) to reflect minor model adjustments. 
 
We note our model and valuation does not currently include Myqorzo sales in nHCM.

Citizens⬆️the PT on Top Pick $CYTK to $96 and reiterated at Market Outperform. 
$EWTX $BMY 
Here&#39;s what Citizens said in its note to investors: 
Cytokinetics remains our top pick ahead of ACACIA-HCM results next quarter; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $96 from $88. 
 
Yesterday afternoon, Cytokinetics reported 4Q25 financial results and business updates, providing insights into the initial weeks of the MYQORZO launch in obstructive hypertrophic cardiomyopathy (oHCM). 
HCPs are becoming certified for the REMS program (both current CMI and new-to-class prescribers), and prescriptions are being written and dispensed. 
 
As expected, many of the questions on the call focused on the upcoming Phase 3 non-obstructive HCM readout, and we continue to view the stock as a top pick ahead of these results.

StockTwits Web

Cytokinetics Inc

Edgewise Therapeutics Inc

Bristol-Myers Squibb Co.

Quantumup

Leerink reiterated $CYTK Outperform; PT $84 
$EWTX $BMY 
Here&#39;s what Leerink said in its note: https://x.com/Quantumup1/status/2031379784224133249?s=20

 to $85 and reiterated at a Buy rating. 


 
Needham said in its note: 
There was little in terms of a Myqorzo launch update in CYTK's 4Q25 update given the product only became commercially available in late-Jan. It will take 2-3 quarters to see how the launch is tracking and compares vs. Camzyos which generated sales of~$53MM in its first 4 qrtrs of launch. 
 
The upcoming 2Q26 readout of ACACIA-HCM in nHCM represents the key catalyst for CYTK, given its potential to not only meaningfully expand (potentially double) Myqorzo's market potential into nHCM but also significantly differentiate vs. Camzyos. 
 
We expect results in early-2Q26, with success likely achieved by meeting one or both of the dual primary endpoints (KCCQ or pVO2). 
 
We maintain our Buy rating and increase our $ PT to $85 (from $84) to reflect minor model adjustments. 
 
We note our model and valuation does not currently include Myqorzo sales in nHCM.